Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Black Diamond Therapeutics Inc
BDTXCurrent price
2.20 USD
-0.04 USD (-1.79%)
Last closed
2.21 USD
Company
www.blackdiamondtherapeutics.com
ISIN
US09203E1055
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
149 384 672 USD
Yield for 12 month
-17.60 %
1Y
3Y
5Y
10Y
15Y
BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: One Main Street, Cambridge, MA, United States, 02142
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
14.50 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-437 000 USD
Last Year
-3 238 000 USD
Current Quarter
-86 000 USD
Last Quarter
-86 000 USD
Key Figures BDTX
1 year
3 years
5 years
10 years
EBITDA
-81 017 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-32.78 %
PEG Ratio
–
Return On Equity TTM
-63.09 %
Wall Street Target Price
14.50 USD
Revenue TTM
–
Book Value
1.72 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.37 USD
Diluted Eps TTM
-1.37 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics BDTX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History BDTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation BDTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-1.92
Price Book MRQ
1.53
Financials BDTX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators BDTX
For 52 weeks
2.31 USD
7.66 USD
50 Day MA
2.93 USD
Shares Short Prior Month
5 936 311
200 Day MA
4.69 USD
Short Ratio
11.67
Shares Short
6 125 851
Short Percent
18.22 %
BeatStart